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EXPERT OPINION
Abstract: Attention deficit hyperactivity disorder (ADHD) is a common chronic condition
with childhood onset that can continue into adulthood. Medication is a fundamental element
in the management of this disorder. Atomoxetine is the newest nonstimulant medication
approved by the United States Food and Drug Administration (FDA) for the treatment of
ADHD. It is the only nonstimulant medication approved by the FDA for treatment of adult
ADHD. Atomoxetine is a norepinephrine reuptake inhibitor that selectively inhibits the
presynaptic norepinephrine transporter. A growing body of literature supports the use of
atomoxetine both in children and adults with ADHD. This paper summarizes information
from the literature about atomoxetine, including pharmacokinetics, pharmacodynamics, clinical
trials, dosing, and side-effects.
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Introduction
Attention deficit hyperactivity disorder (ADHD) is a childhood onset psychiatric
disorder that occurs in 3%–7% of children, with an unknown but lower prevalence
in adults. The disorder can result in significant psychosocial dysfunction in academic
performance, occupational success, and social interactions. The patient with ADHD
is also at increased risk for a number of comorbidities including oppositional defiant
disorder, conduct disorder, depression, anxiety, and substance abuse (APA 2000)
Dysfunction in the transmission of dopamine and norepinephrine has been detected
in this disorder and medications that target the catecholaminergic system have been
identified as efficacious for treatment (Spencer, Biederman, et al 2002).
Atomoxetine was originally named tomoxetine, with initial research completed
for an indication of the treatment of major depression (Zerbe et al 1985). Phase III
trials were completed and initial data suggested it was a potentially effective treatment
for depressive illness. However, development of the drug for the treatment of
depression was discontinued in 1990 for unclear reasons. In 1996, the medication
was re-presented as a potential treatment for ADHD (Preti 2002). The medication
was renamed atomoxetine to avoid confusion with the cancer drug tamoxifen.
 Atomoxetine is the newest nonstimulant medication for the treatment of ADHD
and the first nonstimulant with an indication from the Federal Drug Administration
(FDA) for the management of ADHD in children over 6 years of age, adolescents,
and adults. Stimulant medications are effective for up to 80% of patients with ADHD,
but a portion of patients do not respond or are unable to tolerate problematic side-
effects (Wilens and Spencer 2000). In addition, the possibility of misuse may be a
concern, especially in patients with a history of substance abuse. Atomoxetine presents
an alternative medication in the treatment of this disorder. This paper reviews
information about atomoxetine including pharmacology, open and blinded clinical
trials, case reports, dosage and administration, and safety profile.
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Pharmacology
Pharmacokinetics
Atomoxetine is absorbed through the gastrointestinal tract
with peak levels in 1.83 hours in pediatric patients and 1–
1.5 hours in adult patients. A high fat meal decreases the
rate of absorption but has no effect on the amount of
absorption. Peak levels with a high fat meal are at about 4–
4.5 hours. Once absorbed, 99% of the medication is bound
to albumin. The active metabolite, 4-hydroxyatomoxetine,
is about 67% protein bound. The medication is primarily
distributed into total body water. Comparison of once-daily
and twice-daily dosing does not demonstrate differences in
steady-state profiles. Atomoxetine is not an inducer or
inhibitor of any cytochrome P 450 system. It is metabolized
to active 4-hydroxyatomoxetine by the CYP isoenzyme 2D6.
This metabolite is rapidly made inactive by glucuronidation.
It is excreted in the urine (80%) and feces (17%), with the
remaining amount excreted as unchanged atomoxetine (Eli
Lilly 2003).
Approximately 7% of Caucasians, 1% of Asians
(Poolsup et al 2000), and a variable percentage of blacks
(Wennerholm et al 1999) are poor metabolizers for CYP
isoenzyme 2D6. Thus, in certain populations there may be
significant alterations in pharmacokinetics. The half-life of
atomoxetine has been found to range from 5.2 hours in rapid
metabolizers to 21.6 hours in slow metabolizers. The half-
life of the active metabolite, 4-hydroxyatomoxetine, has
been found to range from 6 to 8 hours in rapid metabolizers,
and from 34 to 40 hours in slow metabolizers. The average
steady-state plasma concentrations are about 10 times greater
in slow metabolizers in comparison with fast metabolizers.
Bioavailability has been shown to vary significantly, from
63% in rapid metabolizers to 94% in slow metabolizers (Eli
Lilly 2003). Despite these differences in half-life,
concentration, and bioavailability, the number and severity
of side-effects appear to be similar across 2D6 phenotypes
(Sauer et al 2005). Future research will establish if CYP2D6
genotyping will be a useful tool for determining appropriate
dosing schedules for patients taking atomoxetine (deLeon
et al 2006)
The pharmacokinetics of atomoxetine in the child and
adolescent population were studied in 21 patients aged
7–14 identified as extensive metabolizers of CYP2D6.
The medication reached peak plasma concentrations 1–2
hours after dosing. Half-life of the medication after a
single dose and at steady state ranged from 3.12 to 3.28
hours. These data were noted to be similar to previous
studies of atomoxetine in adults, with the conclusion that
the 2D6 isoenzymes appeared to be mature in this
population (Witcher et al 2003). Earlier studies have
suggested that the CYP2D6 system is likely fully
developed by several months of age (Kearns 1995).
Atomoxetine is also metabolized to the relatively inactive
metabolite N-desmethylatomoxetine through the CYP
isoenzyme 2C19. However, this is a small portion of the
metabolism. Medication effect appears to last
significantly longer than the half-life.
Pharmacodynamics
The noradrenergic system is important for sustained
attention, learning, memory, and adaptive response. The
right dorsal prefrontal cortex is a key system for attention
regulation and inhibition (Arnsten et al 1996). Atomoxetine
is a specific norepinephrine reuptake inhibitor which
functions by selective inhibition of the presynaptic
norepinephrine transporter resulting in increased
noradrenergic transmission. Extracellular dopamine and
norepinephrine have been shown to increase threefold in
the prefrontal cortex with atomoxetine in animal models
(Bymaster et al 2002). Interestingly, there appears to be no
effect on extracellular dopamine levels in the striatum or
nucleus accumbens, where drugs of abuse elicit a reward
response. This is possibly due to the higher ratio of
noradrenaline transporters relative to dopamine transporters
in the prefrontal cortex compared with the striatum and
nucleus accumbens. The medication appears to have
minimal affinity for muscarinic, serotonergic, cholinergic,
and adrenergic receptors, and serotonin and dopamine
transporters.
In an attempt to better understand the neurobiology of
ADHD and the effects of stimulants and atomoxetine, a
study examined medication effects on inhibitory and
excitatory processes in 9 healthy right-handed adults.
Conditioned and unconditioned motor-evoked potential
amplitudes were measured with paired and single
transcranial magnetic stimulation of the motor cortex.
Measurements were completed at 2 visits separated by 1
week. One visit analyzed processes before and after a single
dose of methylphenidate 30 mg and 1 visit analyzed
processes before and after a single dose of atomoxetine
60 mg. Both medications decreased cortical inhibition and
increased cortical facilitation. There were no significant
differences in physiologic effects between the two
medications (Gilbert et al 2005).Neuropsychiatric Disease and Treatment 2006:2(4) 457
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Efficacy studies
The drug development of atomoxetine for the treatment of
ADHD in adults, adolescents, and children proceeded
methodically, with the initial trials in adults followed by
open-label safety trials in children. At this juncture, proof-
of-concept trials were conducted in children followed by
placebo controlled trials that considered appropriate dosing
and then longer-term use. The process used in the
development of atomoxetine has been noted to be a positive
model for the development of treatments specifically
directed towards children and adolescents (Prasad 2005).
Open trials
An open-label trial with 10 male subjects, ages 9–14 was
conducted over 10 weeks. Baseline and post-treatment
measurements included the ADHD Rating Scale-IV-Parent
Version, Clinical Global Impressions-ADHD-Improvement
Scale, and Conners Parent Rating Scale-Revised: Short
Version. Eight subjects completed the study, with 7 of the 8
demonstrating medication efficacy. One subject withdrew
after developing a rash which occurred for a second time
when the medication was reintroduced. Six of the 10 subjects
had temporary suppression of appetite. Four subjects
experienced transient gastrointestinal symptoms, 3 subjects
experienced irritability, and 3 subjects experienced fatigue
(Kratochvil et al 2001).
An open-label trial with 30 subjects, ages 7–14, was
conducted over 11 weeks. Subjects received 1.9 mg/kg daily
in 2 divided doses. Eight subjects discontinued treatment
with only 2 reporting a side-effect (mild headaches) in
conjunction with noncompliance; the other 6 were
discontinued in the study for a variety of situational issues
(eg, noncompliance, relocation). Response to medication
was assessed with the ADHD Rating Scale-IV-Parent
Version, Clinical Global Impressions-ADHD-Improvement
Scale, and Conners Parent Rating Scale-Revised: Short
Version. Of the 22 subjects who completed the trial, 75%
were identified as positive responders to medication.
Adverse events were reported in 83.3% of subjects. All
adverse events were minor and included rhinitis, headache,
anorexia, dizziness, nervousness, and somnolence. Increases
were noted in blood pressure and heart rate.
Electrocardiograms (EKG) did not show any medication
effect on conduction, repolarization, or rhythm. Blood
chemistries also appeared unaffected by the medication trial.
Three patients with comorbid anxiety and 1 patient with
comorbid depression demonstrated improved anxiety and
depressive symptoms as measured by the Clinical Global
Impression-Anxiety Scale and Clinical Global Impression-
Major Depression Scale (Spencer et al 2001).
In a randomized, prospective open-label trial, 228
subjects were randomized to atomoxetine treatment (n=184)
or methylphenidate treatment (n=44) for 10 weeks. Sixty-
six subjects taking atomoxetine discontinued treatment, 10
because of side-effects (5.4%), 10 because of lack of efficacy
as perceived by the subject (5.4%), and 19 because of lack
of efficacy as perceived by the subject and physician
(10.3%). Nineteen subjects taking methylphenidate
discontinued treatment, 5 because of side-effects (11.4%),
1 because of lack of efficacy as perceived by the subject
(2.3%), and 5 because of lack of efficacy as perceived by
the subject and physician (11.4%). Medication response was
assessed with the ADHD-IV Rating Scale-parent version
only. Both groups demonstrated significant improvements
in ADHD symptoms. Statistically significant increases were
reported for blood pressure and pulse for both medications.
There were no changes on EKG results or blood chemistries.
Common adverse events in the atomoxetine treatment group
included headache, abdominal pain, anorexia, nervousness,
vomiting, somnolence, nausea, and insomnia (Kratochvil
et al 2002).
A prospective, open study was completed on 604
children and adolescents at 33 sites in the UK, continental
Europe, Israel, South Africa, and Australia for 10 weeks.
Symptoms were measured with the ADHD Rating Scale and
the Child Health Questionnaire. ADHD scores were found
to decrease by 56.7%, with 69% of patients rated as having
no or minimal symptoms (Buitelaar et al 2004).
An open trial of atomoxetine was completed on 7
children with ADHD who had previously failed stimulants.
The medication was begun at 0.5 mg/kg daily titrating up to
1.4 mg/kg daily at day 4. Behavior was measured with the
Hyperactivity Index of the Conners Teacher’s Rating Scale.
No improvement was seen on this scale after treatment was
instituted, although number of weeks on medication was
not specified in this trial (Velcea et al 2004).
Results from an ongoing 3-year open label study of 384
adult patients at 31 sites were reported at a period of up to
97 weeks. The Conners’ Adult ADHD Rating Scale-
Investigator Rated Screening version (CAARS-Inv) was
used to assess total ADHD symptoms. Mean CAARS-Inv
scores decreased 33.2% from baseline with adverse events
including increased heart rate, blood pressure, and a slight
decrease in weight (Adler et al 2005).Neuropsychiatric Disease and Treatment 2006:2(4) 458
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The predictive potential of the P300 response was
assessed for identifying patients who would respond to
atomoxetine. Seventeen patients ages 6–17 were
administered P300 testing and then completed a trial of
atomoxetine. Medication response was measured with the
ADHD rating scale-parent version as rated by the
investigator. A mean auditory P300 amplitude of 6.8 microV
predicted a positive response to atomoxetine with a positive
predictive value of 0.88 and a negative predictive value of
0.67 (Sangal et al 2005).
A retrospective chart review was completed on 7 patients
with pediatric Bipolar Disorder and ADHD who received
treatment with atomoxetine. Six of the 7 patients had a
positive response. No patients demonstrated symptoms of
hypomania or mania. Side-effects identified included
sedation, nausea, and decreased appetite (Hah and Chang
2005).
Controlled trials
Adults
A double-blind, placebo-controlled crossover study of
atomoxetine was completed in 22 adults with a diagnosis
of ADHD. Thirteen of the 22 patients (59%) had a comorbid
psychiatric diagnosis. Patients were treated in 3-week
increments with titration up to 80 mg/day by the second
week. There was a 1-week washout between treatment
periods. An average dose of 76 mg/day was well tolerated.
Improvement was established as a 30% reduction on the
ADHD Rating Scale which was administered weekly.
Eleven patients demonstrated improvement while on
atomoxetine while 2 patients demonstrated improvement
while on placebo. Improvements were also noted in the
Stroop Color Word test and Interference T test. One patient
chose to discontinue treatment while on atomoxetine, after
developing anxiety and irritability during the second week
of the trial. An additional patient developed anxiety, 1
developed anxiety and insomnia, and 3 developed insomnia,
all while receiving atomoxetine. While the response rate
was described as modest, it was noted to be comparable
with adult ADHD response rates to other medications
indicated for treatment of ADHD in adults (Spencer et al
1998).
Michelson et al (2003) completed 2 randomized,
placebo-controlled studies on the use of atomoxetine in
adults with 280 patients at 17 sites in study I and 256 patients
at 14 sites in study II. Diagnosis of ADHD was obtained
through clinical interview with the Conners’ Adult ADHD
Diagnostic Interview for DSM-IV. Symptoms were
corroborated by a second reporter or with report of childhood
symptoms from a parent or older sibling. Symptoms were
required to be of at least moderate symptom severity. Most
patients were male, with 72% of patients meeting criteria
for combined type ADHD. About 27% of patients in both
study groups met criteria for ADHD-inattentive type with
less than 1% meeting criteria for ADHD-hyperactive–
impulsive type. Patients with serious medical illness, mood,
anxiety, or psychotic disorders were excluded from the study.
Patients had an initial 1-week medication washout phase
followed by a 2-week placebo phase. Patients who did not
respond in the placebo phase were then randomized to
placebo or atomoxetine for a 10-week period. Atomoxetine
doses ranged from 60 to 120 mg/day. Symptom improvement
was measured with the CAARS Total ADHD Symptom
Score. Both studies demonstrated significant reductions in
CAARS scores, with study II finding significant
improvement in social, family, and work function as
measured by the Sheehan Disability Scale (Michelson et al
2003).
A more recent study examined the potential of
atomoxetine as a weight-reduction medication. A 12-week,
randomized, double-blind, placebo-controlled trial was
completed, with 15 obese women receiving atomoxetine
(final dose 100 mg/day) and 15 obese women receiving
placebo. Measurements included bodyweight, waist
circumference, blood pressure, heart rate, fasting plasma
glucose and lipids, and depressive symptoms. The
atomoxetine group lost significantly more bodyweight than
the placebo group (p<0.0001) and side-effects were reported
as minimal (Gadde et al 2006).
Children and adolescents
The earliest controlled studies in patients under age 18 were
completed in 2002 with proof-of-concept studies. The two
12-week studies were stratified, randomized, double-blind,
placebo-controlled trials in a combined total of 291 children
from age 7 to 12. About one third of the patients met criteria
for comorbid oppositional defiant disorder with lesser
frequencies of anxiety, mood, and elimination disorders. The
study began with a 2-week medication washout period
followed by a 9-week acute treatment phase followed by a
1-week drug discontinuation phase. Children with a previous
trial of stimulant medication received either atomoxetine
or placebo. Children without a previous stimulant trial were
randomized to atomoxetine, placebo, or methylphenidate.
Mean dose of atomoxetine at the end of the study was
1.5 mg/kg daily. Efficacy was primarily evaluated with theNeuropsychiatric Disease and Treatment 2006:2(4) 459
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Table 1 Controlled trials of atomoxetine
Type of Study Duration Number of ADHD Age Major findings
(weeks, months) patients range of
patients
(years)
Double-blind, placebo, crossover 3-wk increments with 1-wk 22 Adults Modest response rate on the
(Spencer et al 1998) washout between trials ADHD Rating Scale
Randomized, placebo, multisite 1-wk washout phase followed 280 Adults Significant reduction in CAARS
(Michelson 2003)  by 2-wk placebo phase scores
followed by 10-wk trial
Randomized, placebo, multisite 1-wk washout phase followed 256 Adults Significant reduction in CAARS
(Michelson et al 2003) by 2-wk placebo phase scores
 followed by 10-wk trial
Stratified, randomized, double-blind, 2-wk washout followed by Combined total of 291 At least 7 Significant reduction in ADHD
placebo (2 trials) 9-wk treatment phase but less Rating Scale scores
(Spencer, Heiligenstein, et al 2002) followed by a 1-wk than 13 yrs
discontinuation phase  
Double-blind, placebo 6 wks 170 6–16 yrs Significant improvements noted
(Michelson et al 2002) on the ADHD Rating Scale, CGI,
and CPRS-short version
Double-blind, placebo, multisite 12- to 18-day washout 297 8–18 yrs Significant improvements noted
(Michelson et al 2001) phase followed by 8-wk trial on the ADHD Rating Scale, CGI
Double-blind, placebo, multisite 8 wks 197 6–12 yrs Significant improvements noted
(Kelsey et al 2004) on the ADHD Rating Scale
Randomized, double-blind, 9 mo 416 patients with 6–15 yrs Relapse in 22.3% of patients
placebo, multi site prior + response on atomoxetine compared to
(Michelson et al 2004) to atomoxetine in an 37.9% in patients on placebo
open study
Randomized, double-blind, 8 wks 293 patients 8–18 yrs Significant improvements on the
placebo(Newcorn et al 2005) (39% with comorbid  ADHD Rating Scale.
ODD) Improvements in ODD
symptoms at higher dose of
atomoxetine 
Randomized, placebo, double-blind 7 wks 153 8–12 yrs Significant improvements on
(Weiss et al 2005) Teacher Ratings on the ADHD
Rating Scale. 
Randomized, placebo, double-blind 2 wks of placebo followed 176 patients with a 8–17 yrs Significant improvements on the
(Sumner et al 2005) by 10-wk trial comorbid anxiety ADHD Rating Scale, Pediatric
disorder  Anxiety Rating Scale,
Multidimensional Anxiety Scale
for Children
Randomized, placebo, double-blind 9 wks 142 patients with 12–18 yrs Both placebo group and
(Bangs et al 2005) comorbid major depression atomoxetine group
demonstrated improvement in
depression symptoms
Double-blind, placebo, multisite 9 wks Subset of 52 girls 7–13 yrs Significant improvement noted on
(Biederman et al 2002) extrapolated from ADHD Rating Scale, CPRS-
sample of 291 ADHD Index, and CGI
Double-blind, randomized, placebo 9 wks Subset of 98 patients with 7–13 yrs Improvement in ADHD only, no
(Kaplan et al 2004) comorbid ODD improvement in ODD symptoms
Abbreviations: ADHD, attention deficit hyperactivity disorder; CAARS, Conners’ Adult ADHD Rating Scale; CPRS, Conners’ Parent Rating Scales; ODD, oppositional
defiant disorder; CGI, clinical global impression.Neuropsychiatric Disease and Treatment 2006:2(4) 460
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ADHD Rating Scale-IV with the Clinical Global
Impressions-ADHD Severity, Conners’ Parent Rating Scale-
Revised: Short Form used for secondary analysis. In each
trial atomoxetine was found to reduce ADHD Rating Scale
scores significantly more than placebo. Six patients
discontinued medication owing to adverse events including
irritability, chest pain, aggression, tic-like movements, and
vomiting. Frequently reported adverse events included
headache, abdominal pain, rhinitis, decreased appetite, and
pharyngitis. Twenty-two percent of patients reported a
decrease in appetite compared with 7% in the placebo group.
The mean weight loss in the atomoxetine group was 0.5 kg.
Very slight but statistically significant increases in diastolic
blood pressure and pulse were noted (Spencer, Heiligenstein,
et al 2002)
A double-blind, placebo study was completed with
170 children and adolescents, ages 6–16 years. Subjects
were randomly assigned to receive placebo or
atomoxetine in once-daily dosing for 6 weeks.
Atomoxetine was begun at 0.5 mg/kg daily for 3 days,
increased to 0.75 mg/kg daily for 4 days, and then titrated
to 1.0 mg/kg daily. In those subjects who continued to
demonstrate significantly elevated symptoms, the dose
was increased to 1.5 mg/kg daily at 4 weeks. Two percent
of patients on atomoxetine discontinued medication
owing to adverse events (vomiting, somnolence). One
patient in the placebo group discontinued owing to
emotional lability. While 19 patients reported nausea or
vomiting, this side-effect appeared to resolve over time.
Other adverse events included asthenia, dizziness,
headache, and rhinitis. Statistically significant
improvements were noted on the ADHD Rating Scale-
IV-Parent Version, Clinical Global Impressions-ADHD-
Improvement Scale, and Conners Parent Rating Scale-
Revised: Short Version. A daily diary was kept by parents
to assess length of efficacy through the day. It should be
noted the daily diary measurements have not been studied
for psychometric characteristics. However, in reviewing
the daily diaries, there was evidence that medication
effect continued to be present later in the day, despite
the short half-life, even with the once-daily dosing
(Michelson et al 2002).
Michelson et al (2001) completed a 13-site double-
blind placebo study of atomoxetine in patients ages 8–
18 years. The medication was begun after a 12- to 18-
day evaluation and a medication washout period. The 297
subjects were randomized to daily doses of 0.5 mg/kg,
1.2 mg/kg, and 1.8 mg/kg or placebo medication.
Approximately 71% of the subjects were male.
Medication or placebo was given in 2 divided doses over
an 8-week period. Response was measured by the ADHD
Rating Scale, the Conners’ Parent Rating Scale-Revised:
Short Form, the Clinical Global Impressions-Severity
scale, Children’s Depression Rating Scale-revised, and
the Child Health Questionnaire. Significant improvement
was noted in social and family functioning as well as the
core ADHD symptoms of inattention, hyperactivity, and
impulsivity at the daily doses of 1.2 mg/kg and 1.8 mg/
kg. Some data supported a graded dose-response. While
baseline scores on the CDRS-R were subclinical,
improvement was still noted on this measure in the higher
atomoxetine dose groups compared with placebo. Of
interest, this study also examined response differences
between rapid and slow CYP 2D6 metabolizers. Results
indicated improvement in both groups, with greater
improvement seen in slow metabolizers than rapid
metabolizers. As these groups were small, however,
statistical measurements could not be computed
(Michelson et al 2001).
Once-daily dosing of atomoxetine in 197 children, ages
6–12 years was assessed in a double-blind, placebo-
controlled trial over 8 weeks at 12 outpatient sites.
Symptoms were assessed with the ADHD Rating Scale-IV.
The mean daily dose was 1.3 mg/kg. Significant
improvement was noted in the atomoxetine group which
extended into evening hours as well as morning hours.
Adverse events occurring more frequently in the
atomoxetine treated group included decreased appetite,
somnolence, and fatigue (Kelsey et al 2004).
A randomized, double-blind, placebo-controlled study
was completed over 9 months in a group of children and
adolescents who had responded to atomoxetine in a 12-week
open study. A total of 416 patients were randomized to
atomoxetine or placebo. The ADHD Rating Scale-IV,
Clinical Global Impressions-Severity scale, and Child Health
Questionnaire were used to assess patients at the end of 9
months. Mean dose at the end of the study was 1.56 mg/kg
daily. Relapse, defined as a return to 90% of baseline
symptom severity, was found in 22.3% of patients on
atomoxetine compared with 37.9% of patients on placebo.
In addition, patients receiving atomoxetine demonstrated
superior psychosocial functioning than patients receiving
placebo. Nine of 292 patients receiving atomoxetine
discontinued medication because of adverse events
compared with 1 of 124 patients in the placebo group.
Gastroenteritis and pharyngitis were more common adverseNeuropsychiatric Disease and Treatment 2006:2(4) 461
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events in the atomoxetine group. This group also gained
weight more slowly than the placebo group. No significant
differences between the two groups were found on routine
labs or cardiovascular measures (Michelson et al 2004).
A randomized, double-blind placebo study completed
on 293 children and adolescents with ADHD for 8 weeks
assessed response with the ADHD Rating Scale IV-Parent
Version (investigator scored), Conners’ Parent Rating Scale-
Revised-Short Form, Clinical Global Impressions-ADHD-
Severity Scale and the parent-rated Child Health
Questionnaire. Thirty-nine percent of the patients had
comorbid oppositional defiant disorder. Both groups
responded significantly to atomoxetine compared with
placebo at 1.8 mg/kg daily. The ADHD-only group
responded significantly better to atomoxetine than placebo
at 1.2 mg/kg daily but the group with ADHD and
oppositional defiant disorder (ODD) did not. It was proposed
that possibly children and adolescents with ADHD and ODD
may require higher doses for a positive response to
medication (Newcorn et al 2005).
The efficacy of once-daily atomoxetine was assessed in
a randomized, placebo-controlled study of 153 children with
ADHD. Atomoxetine up to 1.8 mg/kg daily was administered
for 7 weeks. Teacher ratings using the ADHD Rating Scale-
IV, Teacher Version were utilized based on an investigator
phone interview with the teacher. The total scores as well
as the inattentive and hyperactive–impulsive subscales were
significantly improved in the group receiving atomoxetine.
Six patients discontinued medication owing to adverse
events including abdominal pain, emotional disturbance,
feeling abnormal, and vomiting. No patients in the placebo
group discontinued medication (Weiss et al 2005).
In a 12-week randomized trial, 176 patients ages 8–17
with ADHD and an anxiety disorder (generalized anxiety
disorder, separation anxiety disorder, or social phobia
disorder) were randomized to receive atomoxetine or
placebo. After receiving 2 weeks of placebo medication,
the atomoxetine group received 1.2 mg/kg daily of
medication in twice-daily dosing. Symptoms were assessed
with the ADHD Rating Scale, the Pediatric Anxiety Rating
Scale, and the Multidimensional Anxiety Scale for Children.
There was significant improvement in ADHD symptoms as
well as significant improvement in anxiety compared with
placebo. Decreased appetite was the one adverse event that
occurred more commonly in the atomoxetine group (Sumner
et al 2005).
One hundred forty-two patients ages 12–18 with ADHD
and major depression were randomized to receive
atomoxetine or placebo for 9 weeks. Most patients were
male. The target atomoxetine dose was 1.2 mg/kg daily with
the possibility of increase to 1.8 mg/kg daily if needed.
Response to medication was measured with the ADHD-
Rating Scale, Children’s Depression Rating Scale and Young
Mania Rating Scale. Both the atomoxetine group and the
placebo group demonstrated significant improvement in
depression symptoms. Two patients in each group
demonstrated the appearance of mania. Nausea and
decreased appetite were more common in the atomoxetine
group. No suicidal ideation or behavior was noted in either
group (Bangs et al 2005).
A subset of 52 girls, ages 7–13, was extrapolated from
a larger sample of 291 children with ADHD, to participate
in a double-blind, placebo-controlled, multisite study
comparing atomoxetine with placebo over a 9-week
period. One subject was unable to complete the study
secondary to a personal conflict. Behaviors were
measured with the ADHD Rating Scale, Conner’s Parent
Rating Scale-Revised ADHD Index and Clinical Global
Improvement Scale – ADHD short form. A statistically
significant improvement was documented for both
inattention and hyperactive–impulsive behaviors. Only
1 patient discontinued from both the atomoxetine group
and placebo group for side-effects. The most common
side-effects were abdominal pain (29%), rhinitis (26%),
and headache (26%) (Biederman et al 2002).
Another subset analysis was completed on 98 child
patients from 2 sites where double-blind, randomized,
placebo-controlled trials were being completed. Children
with ADHD as well as ODD were identified with the
Diagnostic Interview for Children and Adolescents-IV
(DICA-IV), the ADHD Rating Scale-IV-Parent Version,
Investigator Administered/Scored, Conners’ Parent Rating
Scales-Revised, short version, and the Clinical Global
Impression-ADHD Severity Scale. While the patients were
found to improve on ADHD ratings in this subgroup, ODD
symptoms were not found to improve with atomoxetine
(Kaplan et al 2004).
As noted in some of the above studies, atomoxetine has
been studied in groups of children and adolescents with
ADHD and the comorbid condition of Oppositional Defiant
Disorder. It has been suggested that efficacy of atomoxetine
in the autism spectrum population should be studied, as this
population frequently presents with hyperactive–impulsive
behaviors, and aggression. (Aman 2004) Other populations
that would potentially benefit from further study include
preschool age children with ADHD, patients with epilepsyNeuropsychiatric Disease and Treatment 2006:2(4) 462
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(Schubert 2005), and patients with sleep disturbance (Steer
2005).
Comparisons in response to atomoxetine were analyzed
for children ages 6–11 (510 receiving atomoxetine, 341
receiving placebo) and adolescents ages 12–17 (107
receiving atomoxetine, 69 receiving placebo). Responses
were measured with the ADHD Rating Scale, Conners’
Parent Rating Scale, and Clinical Global Impressions of
Severity. Adolescents were noted to have lower baseline
ADHD scores. Both groups responded to treatment with
atomoxetine with no statistical differences in response rates
between the two groups. Children were noted to have higher
rates of somnolence and headaches compared to placebo
(Wilens et al 2006).
Safety
Atomoxetine has been shown to be a well-tolerated and safe
medication alternative to the stimulants for the treatment of
ADHD. Clinical trials to date have focused on short-term
use; data on the safety of long term use are not yet available.
Side-effects
The most common side-effects include headache, abdominal
pain, nausea, vomiting, decreased appetite, weight loss,
irritability, insomnia, and sedation. In adults, there have been
reports of urinary retention, erectile dysfunction,
dysmenorrhea, and decreased libido (Michelson et al 2003).
Less common but significant side-effects that have been
reported include elevated liver enzymes (Eli Lilly and
Company 2004 December 21, pers comm), and motor tics
(Lee et al 2004; Ledbetter 2005). However, an 18-week,
double-blind, randomized, placebo trial was completed with
148 patients with ADHD and a comorbid tic disorder ages
7–17. Tics were measured with the Yale Global Tic Severity
Scale. Atomoxetine did not exacerbate tics and there was a
trend for improvement of tics in the atomoxetine group
compared with the placebo group (Allen et al 2005). There
are several reports regarding induction of mania (Steinberg
et al 1985; Henderson 2004; Henderson and Hartman 2004)
and a report of an allergic reaction with angioneurotic edema
and urticaria (Spencer et al 1998). A study reviewing
cardiovascular measurements indicated an increase in mean
change for heart rate and blood pressure but no changes in
the QTc interval. Effects on blood pressure and heart rate
remained during atomoxetine treatment, resolving with
discontinuation of the medication (Wernicke et al 2003). In
adult trials there has been an increased rate of urinary
retention or hesitation compared with the placebo group.
(Eli Lilly 2003) Thus, complaints of urinary retention or
hesitation may be related to the use of atomoxetine.
More recent concerns have focused on more serious side-
effects. There have been 2 reports of elevated liver enzymes
in patients taking atomoxetine. The enzymes normalized in
both patients after the atomoxetine was discontinued. In one
patient elevated liver enzymes and jaundice recurred when
the medication was resumed. The current recommendation
is to monitor for fatigue, jaundice, right upper quadrant
tenderness, dark urine, and unexplained flu-like symptoms.
Regular monitoring of liver enzymes is not recommended
at this time (Eli Lilly and Company 2004 December 21,
pers comm).
More controversial is the recent report of an increased
risk of suicidality associated with the medication that has
resulted in the addition of a black box warning by the FDA.
Comments in the black box warning include the following:
“Strattera (atomoxetine) increased the risk of suicidal
ideation in short-term studies in children or adolescents with
ADHD. Anyone considering the use of Strattera in a child
or adolescent must balance this risk with the clinical need.
Patients who are started on therapy should be monitored
closely for suicidality (suicidal thinking and behavior),
clinical worsening, or unusual changes in behavior. Families
and caregivers should be advised of the need for close
observation and communication with the prescriber.” (Eli
Lilly and Company 2005 November 4, pers comm). An
independent review of reports from the Eli Lilly trials
completed by Greenhill summarized the following data that
prompted the decision: 5 children out of the 1357 receiving
atomoxetine developed suicidal ideation (0.37%) with 2
cases considered to have clinically important levels of
suicidal ideation. One child out of the 1357 was reported to
have attempted to harm himself (0.00074%). This risk was
statistically significant in comparison to the 0 incidence of
suicidal ideation/attempts in the 851 patients who received
placebo. Of the patients reported to have had suicidal
ideation or behavior, all were between the ages of 7 and 12
years. In contrast, no adolescents were reported to have
experienced suicidal ideation. Limited information
regarding the prevalence of suicidal ideation in the general
population or the ADHD population in this age group
prevents accurate analysis of the actual risk associated with
medication use. A recommendation was made for the FDA
to conduct further trials as well as to create an independent
panel of experts to review data on this issue. In addition,
the importance of a comprehensive treatment plan inNeuropsychiatric Disease and Treatment 2006:2(4) 463
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conjunction with medication management has been stressed
(Sarles 2005).
The concerns regarding suicidal ideation raise an
interesting and important issue regarding the classification,
analysis, and understanding of the pharmacodynamics of
atomoxetine. Atomoxetine is currently classified as a
nonstimulant medication for ADHD. The potential side-
effect of agitation, along with what is known about the
neurophysiological response, however, is similar to effects
observed in stimulant medications. Indeed, the definition
of a stimulant from Stedman’s Medical Dictionary is as
follows: “1. Stimulating; exciting to action. 2. An agent that
arouses organic activity, strengthens the action of the heart,
increases vitality, and promotes a sense of well-being;
classified according to the parts upon which they chiefly
act: cardiac, respiratory, gastric, hepatic, cerebral, spinal,
vascular, genital.” Also, emerging research regarding effect
on brain physiology finds similar effects between stimulants
and atomoxetine (Gilbert et al 2005).
In contrast, atomoxetine, which was initially developed
for the treatment of depression, shares common
characteristics with norepinephrine reuptake inhibitor
antidepressants. It is interesting to note that concerns have
also been expressed about suicidal ideation and behavior
related to antidepressants. The link between suicidal
behaviors and antidepressant use remains unclear at this
time, as many confounding issues challenge attempts to
understand this question critically. Psychiatric illnesses,
especially mood disorders, are known to increase the risk
of suicidal ideation and suicide attempts. The retrospective
data analysis on suicide has limitations in that the original
data lacked pretreatment information about suicidal
behaviors and sometimes contained limited information
regarding suicidality (Cheung et al 2006). Proposed
mechanisms of action for the increase in suicidal ideation
with antidepressants includes akasthesia, anxiety, and
restlessness as well as the increase in energy secondary to
treating the underlying disorder of depression. The
relationship between suicidal ideation and medications
including antidepressants and atomoxetine remain unclear.
In summary, atomoxetine shares characteristics with both
stimulant medications and antidepressants, while currently
being classified as a “nonstimulant”. It is possible a similar
mechanism of action is responsible for the risk of suicidal
ideation, behavior, and agitation. Further research is clearly
needed in this area.
Potential for abuse has been assessed in subjects with a
history of substance abuse. There has been no report of
pleasurable effects from taking atomoxetine which implies
a limited abuse potential for this medication (Heil et al 2002).
Consideration should be given for dosing in special
populations. Patients with impaired hepatic function will
require a decrease in dosing. Significant reductions in
clearance of atomoxetine were observed in 10 adult patients
with hepatic impairment compared with 10 adult controls.
The degree of impairment correlated with reduction in
clearance of atomoxetine. The target dose should be reduced
by 25% in patients with moderate hepatic insufficiency to
50% in patients with severe hepatic insufficiency (Chalon
et al 2003; Eli Lilly 2003). Patients with renal insufficiency
do not require alterations of dosing regimen (Eli Lilly 2003).
Atomoxetine should be used with caution in patients with
significant cardiovascular disease as it has been documented
to increase blood pressure and pulse (Wernicke et al 2003).
Overdose
There is at least 1 report of significant complications from
atomoxetine overdose. A 15-year-old male patient took
1200 mg (22 mg/kg) of atomoxetine about 1½ hours before
coming to the emergency room. The patient experienced a
generalized seizure with postictal confusion about 3 hours
after ingestion with a second generalized seizure 2 hours
later. In addition he demonstrated tachycardia with a
prolonged QTc interval of 607 msec 3 hours after ingestion
and 435 msec 6 hours after ingestion. There did not appear
to be additional medications included in the overdose. The
patient’s symptoms resolved and he was discharged to a
psychiatric inpatient facility 2 days after the event (Sawant
and Daviss 2004). Atomoxetine ingestions were reviewed
from the records of 3 regional poison control centers. Forty
patients with follow up data were identified who had taken
atomoxetine alone. Symptoms reported included
tachycardia, drowsiness, nausea, hypertension, and
vomiting. One child was reported to have had a seizure.
The only arrhythmia reported was sinus tachycardia. The
report concluded that activated charcoal and/or observation
were appropriate in the management of atomoxetine
overdose. No clinically significant cardiovascular problems
requiring intervention occurred (Spiller et al 2005).
Drug interactions
Because atomoxetine is metabolized through the CYP2D6
system, interactions can occur with medications that are
inhibitors of this system such as paroxetine, fluoxetine, and
quinidine. Other 2D6 inhibitors include citalopram,Neuropsychiatric Disease and Treatment 2006:2(4) 464
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escitalopram, bupropion, sertraline, chlorpromazine,
hydroxyzine, and clomipramine. Twenty-two healthy
subjects with rapid metabolism of the 2D6 system were
administered 20 mg of atomoxetine to steady state. Twenty
mg of paroxetine was added for 17 days with
coadministration with atomoxetine for the last 6 days.
Paroxetine increased the maximum concentration of
atomoxetine by 3.5-fold and half-life of atomoxetine by 2.5-
fold. There was no change in paroxetine level with the
addition of atomoxetine (Belle et al 2002). It is
recommended to begin treatment at standard doses but
pursue further dose increases with caution. Inducers of this
system include dexamethasone and rifampin. No studies
were found that examine the interaction between
atomoxetine and 2D6 inducers. Atomoxetine has not been
shown to have an effect on the metabolism of other
medications metabolized through 2D6.
Administration of atomoxetine with albuterol may
increase heart rate and/or blood pressure. Administration
with a monoamine oxidase inhibitor (or within 2 weeks of
administration of this agent) is contraindicated because of
the risk of a hypertensive crisis (Eli Lilly 2003).
Administration with methylphenidate does not appear
to increase the risk of cardiovascular problems more than
can occur with methylphenidate alone, but there is limited
research on this combination. A case report reviewed 4 cases
in which patients received a combination of atomoxetine
with a stimulant medication (3 patients on a mixed
amphetamine salt and 1 patient on OROS methylphenidate).
In 2 cases the atomoxetine was added to the stimulant
medication when the patient had difficulty with complete
coverage of ADHD symptoms throughout the day. In the
other 2 cases a stimulant medication was added to
atomoxetine when a partial benefit was observed at a
maximum dose of atomoxetine. In all 4 cases, improvement
in functioning was reported with no evidence of significant
adverse events (Brown 2004).
A randomized, double-blind, placebo study was
conducted on 173 patients ages 7–17 with ADHD and
concomitant anxiety or depression. Patients received
fluoxetine or placebo for 8 weeks in conjunction with
atomoxetine the last 5 weeks. Reductions in ADHD,
depressive symptoms, and anxiety symptoms were marked
in both treatment groups. Overall, the combination of
fluoxetine and atomoxetine was well tolerated, although this
group had greater increases in blood pressure and pulse
compared with the atomoxetine-only group (Kratochvil et
al 2005).
Dosage–administration
Atomoxetine is given at a target dose of 1.4 mg/kg daily
and can be given in a single daily dose or in twice-a-day
dosing. It is recommended to begin at 0.5 mg/kg for 4
days before titrating up to the target dose. Medication
effect may take up to 4 weeks to occur. Patients should
be monitored for medication effect via rating scales
completed initially at 4 weeks. Weight, height (for
growing children and adolescents), blood pressure, and
pulse should be monitored at every visit. Liver function
tests are indicated if there is report of fatigue, jaundice,
right upper quadrant pain, or flu-like illness. If the patient
has pre-existing hypertension, tachycardia, or
cardiovascular disease additional caution is advised, as
atomoxetine has not been studied in patients with these
conditions and the medication is known to slightly
increase blood pressure and pulse.
The medication should not be administered in
conjunction with a monoamine oxidase inhibitor. While
there are no specific recommendations when atomoxetine
is given with albuterol or stimulant medication, careful
monitoring of cardiovascular function is recommended.
Because of concerns about mydriasis, atomoxetine is
contraindicated in patients with narrow-angle glaucoma.
There have been no controlled studies on the use of
atomoxetine in pregnancy. Atomoxetine is currently a
category C medication for use in pregnancy.
In a randomized, double-blind, placebo-controlled trial
of 288 children with ADHD, morning vs evening dosing of
atomoxetine for 6 weeks was evaluated. Children with
ADHD were assessed with the ADHD Rating Scale and the
Clinical Global Impression-Severity Scale. Both groups
responded significantly better than those on placebo.
However, the group receiving a morning dose did better
than the group receiving an evening dose on the
hyperactive–impulsive subscale of the ADHD-RS, and the
CGI-Severity Scale. At this time, the importance of timing
of dose, if any, is not clear. In contrast, a second study that
analyzed response to morning vs evening dosing of
atomoxetine, found the evening dose was reported as better
tolerated. Both groups demonstrated a positive response to
medication (Kelsey et al 2005).
While plasma levels of atomoxetine are not currently
used to direct dosing, a recent study found a correlation
between atomoxetine level and response to medication.
Patients with plasma levels greater than 800 ng/mL showed
a greater, although not a statistically significant,Neuropsychiatric Disease and Treatment 2006:2(4) 465
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improvement in ADHD symptoms. It was noted that in 1
patient, this required a daily dose of 2.4 mg/kg (Dunn et al
2005).
In a prospective, placebo-controlled trial of atomoxetine
in children and adults, patients were monitored for changes
in symptoms and adverse events after discontinuation of
atomoxetine. There was no evidence of a discontinuation
syndrome. Symptoms of ADHD were noted to worsen but
not return to pretreatment levels of severity (Wernicke et al
2004).
Conclusion
Atomoxetine is a novel compound that has clinical utility
both for children and adults with ADHD. It is unclear at
this time whether atomoxetine is also effective in the
treatment of anxiety or depression. Data are also mixed as
to whether children with comorbid ODD demonstrate
improvement of oppositional behaviors secondary to a
medication trial. Further research is needed on efficacy of
atomoxetine in special populations with attentional problems
such as patients with epilepsy or autism spectrum disorders.
Benefits specific to atomoxetine include the once-daily
dosing, sustained medication effect, and lack of risk for
abuse. It is generally well tolerated, with the most common
side-effects including appetite suppression, mild weight loss,
and nausea. Serious but rare potential side-effects may
include agitation, irritability, elevated liver enzymes, rash,
tics, and suicidal ideation. Further research into the
pharmacodynamics and safety of the medication is indicated.
Additional data on the safety of long term use are not
currently available. Atomoxetine is a useful addition to
nonstimulant treatment options for patients with ADHD who
have not responded to stimulant medication or are unable
to tolerate problematic side-effects. Atomoxetine should also
be considered an alternative in patients with ADHD and a
history of substance abuse.
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